This reactivation leads to the inactivation of the JAK2/STAT5 signaling pathway, reversing IM resistance induced by the bone marrow microenvironment, and inhibiting the malignant progression of CML CD34+ cells [65]. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.